15 July 2024

Graft Polymer (UK) Plc

("Graft Polymer" or the "Company")

Director resignation and launch of new corporate website and social media profiles

Graft Polymer (UK) Plc (LON: GPL), an innovative biopolymer drug delivery systems development company, announces the resignation of Mr. Pavel Kobzev from its board of directors with immediate effect. This follows the Company's recent divestiture of its industrial plastics business unit, Graft Polymer D.O.O., announced on 3 May 2024, and the successful completion of its recent fundraise, details of which were announced on 3 July 2024.

Additionally, the Company is pleased to announce the launch of its new corporate website and updated LinkedIn and X (formerly Twitter) profiles. These platforms are designed to reflect the Company's strategic focus on supporting biopharmaceutical companies to enhance the bioavailability, pharmacokinetics, and stability of their therapeutics.

Visit us online:

www.graftpolymer.co.uk

LinkedIn

X (formerly Twitter)

Enquiries

Graft Polymer (UK) Plc

Anthony Tennyson, CEO and Executive Director, Email: anthonytennyson@graftpolymer.co.uk

Yifat Steuer, CFO and Executive Director, Email: yifat@graftpolymer.co.uk

Allenby Capital (Broker)

Nick Naylor / Liz Kirchner / James Reeve (Corporate Finance) 

Guy McDougall (Sales) 

+44 (0) 20 3328 5656 

About Graft Polymer (UK) Plc

Graft Polymer (UK) Plc (LON:GPL) is an innovative developer of biopolymer drug delivery systems dedicated to assisting biopharmaceutical companies in enhancing the effectiveness of their therapeutics. Our proprietary patented platform, a bioabsorbable self-nanoemulsifying drug delivery system (SNEDDS), represents a cutting-edge solution in drug delivery technology. By integrating active pharmaceutical ingredients (APIs) into our novel, patented delivery systems, we enable clients to improve the bioavailability, pharmacokinetics, and stability of their therapeutics.

www.graftpolymer.co.uk | LinkedIn | X (formerly Twitter)